A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Public ClinicalTrials.gov record NCT05562830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A
Study identification
- NCT ID
- NCT05562830
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- MK-3120 Biological
- Pembrolizumab Biological
- Zilovertamab vedotin Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2022
- Primary completion
- Jun 27, 2030
- Completion
- Jun 27, 2030
- Last update posted
- Apr 28, 2026
2022 – 2030
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045) | Orange | California | 92868 | Recruiting |
| University of California San Francisco ( Site 1044) | San Francisco | California | 94158 | Recruiting |
| Anschutz Cancer Pavilion ( Site 1017) | Aurora | Colorado | 80045 | Completed |
| University of Chicago Medical Center ( Site 1037) | Chicago | Illinois | 60637 | Recruiting |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 1011) | Indianapolis | Indiana | 46202 | Recruiting |
| Siteman Cancer Center ( Site 1038) | St Louis | Missouri | 63108 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 1031) | New York | New York | 10065 | Recruiting |
| Cleveland Clinic-Taussig Cancer Center ( Site 1036) | Cleveland | Ohio | 44195 | Recruiting |
| UPMC Hillman Cancer Center ( Site 1014) | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Huntsman Cancer Institute ( Site 1041) | Salt Lake City | Utah | 84112-5500 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05562830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05562830 live on ClinicalTrials.gov.